Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabella Gashaw

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Mechanisms of Development|June 23, 2009
Krüppel-like factor 4, a "pluripotency transcription factor" highly expressed in male postmeiotic germ cells, is dispensable for spermatogenesis in the mouseMaren Godmann, Isabella Gashaw, Jonathan P Katz, et al.
Trials|April 24, 2023
The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosisThomas Reiberger, Annalisa Berzigotti, Jonel Trebicka, et al.
Fertility and Sterility|February 24, 2007
Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissueSabine Fechner, Bettina Husen, Hubert Thole, et al.
Plos One|March 14, 2012
Induction of overt menstruation in intact miceMarion Rudolph, Wolf-Dietrich Döcke, Andrea Müller, et al.
International Journal of Molecular Sciences|November 27, 2025
Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney DiseaseDenis Delic, Isabella Gashaw, Ileana Duran-Fernandez, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|May 29, 2018
Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal WomenRüdiger Nave, Stefan Jodl, Anja Hoffmann, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 13, 2024
Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge testEric J Lawitz, Judith Ertle, Corinna Schoelch, et al.
Investigative Ophthalmology & Visual Science|July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
British Journal of Clinical Pharmacology|May 22, 2024
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young menChristian Friedrich, Dave Singh, Klaus Francke, et al.
Clinical Pharmacokinetics|May 27, 2022
Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized StudyChristian Friedrich, Klaus Francke, Isabella Gashaw, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Mechanisms of Development|June 23, 2009
Krüppel-like factor 4, a "pluripotency transcription factor" highly expressed in male postmeiotic germ cells, is dispensable for spermatogenesis in the mouseMaren Godmann, Isabella Gashaw, Jonathan P Katz, et al.
Trials|April 24, 2023
The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosisThomas Reiberger, Annalisa Berzigotti, Jonel Trebicka, et al.
Fertility and Sterility|February 24, 2007
Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissueSabine Fechner, Bettina Husen, Hubert Thole, et al.
Plos One|March 14, 2012
Induction of overt menstruation in intact miceMarion Rudolph, Wolf-Dietrich Döcke, Andrea Müller, et al.
International Journal of Molecular Sciences|November 27, 2025
Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney DiseaseDenis Delic, Isabella Gashaw, Ileana Duran-Fernandez, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|May 29, 2018
Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal WomenRüdiger Nave, Stefan Jodl, Anja Hoffmann, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|June 13, 2024
Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge testEric J Lawitz, Judith Ertle, Corinna Schoelch, et al.
Investigative Ophthalmology & Visual Science|July 9, 2024
ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2Robyn H Guymer, Rufino Silva, Mercedeh Ghadessi, et al.
British Journal of Clinical Pharmacology|May 22, 2024
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young menChristian Friedrich, Dave Singh, Klaus Francke, et al.
Clinical Pharmacokinetics|May 27, 2022
Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized StudyChristian Friedrich, Klaus Francke, Isabella Gashaw, et al.
Pageof 4